NeuroOne Medical Technologies said this week that it has appointed Camilo Andres Diaz-Botia as director of electrode development.
Diaz-Botia previously led the microfabrication process engineering team at Neuralink, a company that’s developing a high-bandwidth brain-machine interface. Under his direction, the team built and designed novel processes for integration of thin-film neural probes with brain-machine interface systems.
Eden Prairie, Minn.-based NeuroOne is an neuromodulation startup working on minimally invasive and high-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, essential tremors and other related neurological disorders.
“We are thrilled to have such a highly regarded neural engineering expert to lead our development team,” said NeuroOne president & CEO Dave Rosa in a news release. “Camilo brings in-depth knowledge and expertise in the design of implantable thin-film electrodes. His responsibilities and experience at Neuralink, from research and development to manufacturing, expand the depth and breadth of our capabilities to further develop NeuroOne’s portfolio of thin-film electrode technology. As we continue to pursue our vision of developing combination diagnostic and therapeutic electrode technology, we expect Camilo’s leadership and experience will contribute significantly to helping us achieve these goals.”
Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from a joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin-film neural interfaces for chronic implants, developing electrocorticography arrays with silicon carbide (a material suitable for long-term performance in harsh environments) and electrode arrays for minimally invasive subcortical recordings. He has authored and co-authored multiple peer-reviewed scientific articles published in journals, including Journal of Neural Engineering, Neuron and Lab-on-a-Chip.
“I believe NeuroOne’s focus on bringing thin-film devices to patients will have a significant impact in their overall clinical experience,” Diaz-Botia said. “For many years, thin-film technologies have been utilized in academic settings and have matured enough to address a number of clinical needs today. I am excited to be a part of the ongoing development of NeuroOne’s thin film electrodes and furthering NeuroOne’s goal of making these devices commercially available.”